Review



16s rrna pyrosequencing v1-v3 region  (Pyrosequencing Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Pyrosequencing Inc 16s rrna pyrosequencing v1-v3 region
    Summary of the published studies related to the respiratory microbiome in COPD patients.
    16s Rrna Pyrosequencing V1 V3 Region, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/16s+rrna+pyrosequencing+v1-v3+region/16s+rdna++v1+v3++amplicon/pmc09966333-2-25-27
    Average 90 stars, based on 1 article reviews
    16s rrna pyrosequencing v1-v3 region - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Molecular Accounting and Profiling of Human Respiratory Microbial Communities: Toward Precision Medicine by Targeting the Respiratory Microbiome for Disease Diagnosis and Treatment"

    Article Title: Molecular Accounting and Profiling of Human Respiratory Microbial Communities: Toward Precision Medicine by Targeting the Respiratory Microbiome for Disease Diagnosis and Treatment

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms24044086

    Summary of the published studies related to the respiratory microbiome in COPD patients.
    Figure Legend Snippet: Summary of the published studies related to the respiratory microbiome in COPD patients.

    Techniques Used: Microarray, Biomarker Discovery, Control, Bacteria, Sequencing, Sterility, Positive Control, Cloning

    Related Articles

    Real-time Polymerase Chain Reaction:

    Article Title: Molecular Accounting and Profiling of Human Respiratory Microbial Communities: Toward Precision Medicine by Targeting the Respiratory Microbiome for Disease Diagnosis and Treatment
    Article Snippet: 2010 , COPD, asthma and healthy control, France. , 5 , To characterize the bacteria community. , 16S rRNA gene-based sequencing (V3 to V5) from swabs of the nose and oropharynx and brushings of the left upper lobe. The qPCR was used to determine the bacterial load. , They identified 5054 16S rRNA bacterial sequences. Bacteroidetes, particularly Prevotella , were shown to be predominant in healthy white Proteobacteria, particularly Haemophillus , and more frequent in COPD and asthmatics. Nasal microbiota clustered together for all three phenotypes and was most distant from the other two respiratory location samples. The oropharynx and left upper lobe microbiota of COPD clustered together. The bronchial tree was not sterile. , [ ] . .. 2011 , Healthy smokers, nonsmokers, and COPD subjects, USA. , 4 , To explore the differences in the lung microbiome of the three groups. , 16S rRNA pyrosequencing (v1-V3 region). Taxonomic and phylogenetic-based analysis l6s rDNA. The qPCR was used to quantify the total bacterial load. , Healthy smokers, nonsmokers, and mild COPD tend to have a more diverse microbial community than moderate and severe COPD microbiota. There was no significant difference in the microbiota and the bacterial load between the three study groups. A core microbiota was identified and includes: “ Pseudomonas , Streptococcus , Prevotella , Fusobacterium , Haemophillus , Veillonella ”. Significant microanatomic changes in bacterial population were observed within the same lung of advanced COPD patients. , [ ] . .. 2012 , Nonsmokers, non-COPD smokers, GOLD 4 COPD, and CF (positive control), Canada. , 8 , To confirm the presence of a microbiome in the lung and characterize the difference between the groups’ lung microbiome. , Lung tissue samples were used for quantifying the bacterial load using qPCR: 165 rDNA assay, T-RFLP, and Pyrotag sequencing (VI-V3) to characterize the microbiome. , They observed an increase in the Firmicutes phylum in COPD patients compared with all other groups, associated with an increase in the Lactobacillus genus. , [ ] .



    Similar Products

    16s rrna pyrosequencing v1-v3 region  (Pyrosequencing Inc)
    90
    Pyrosequencing Inc 16s rrna pyrosequencing v1-v3 region
    Summary of the published studies related to the respiratory microbiome in COPD patients.
    16s Rrna Pyrosequencing V1 V3 Region, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/16s+rrna+pyrosequencing+v1-v3+region/16s+rdna++v1+v3++amplicon/pmc09966333-2-25-27
    Average 90 stars, based on 1 article reviews
    16s rrna pyrosequencing v1-v3 region - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Summary of the published studies related to the respiratory microbiome in COPD patients.

    Journal: International Journal of Molecular Sciences

    Article Title: Molecular Accounting and Profiling of Human Respiratory Microbial Communities: Toward Precision Medicine by Targeting the Respiratory Microbiome for Disease Diagnosis and Treatment

    doi: 10.3390/ijms24044086

    Figure Lengend Snippet: Summary of the published studies related to the respiratory microbiome in COPD patients.

    Article Snippet: 2011 , Healthy smokers, nonsmokers, and COPD subjects, USA. , 4 , To explore the differences in the lung microbiome of the three groups. , 16S rRNA pyrosequencing (v1-V3 region). Taxonomic and phylogenetic-based analysis l6s rDNA. The qPCR was used to quantify the total bacterial load. , Healthy smokers, nonsmokers, and mild COPD tend to have a more diverse microbial community than moderate and severe COPD microbiota. There was no significant difference in the microbiota and the bacterial load between the three study groups. A core microbiota was identified and includes: “ Pseudomonas , Streptococcus , Prevotella , Fusobacterium , Haemophillus , Veillonella ”. Significant microanatomic changes in bacterial population were observed within the same lung of advanced COPD patients. , [ ] .

    Techniques: Microarray, Biomarker Discovery, Control, Bacteria, Sequencing, Sterility, Positive Control, Cloning